C
Cullinan Oncology D
D
CGEM
22.967
USD
1.13
(5.16%)
مغلق
حجم التداول
13,087
الربح لكل سهم
-3
العائد الربحي
-
P/E
-7
حجم السوق
1,478,034,257
العنوان: Cullinan Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.